Sonnet Biotherapeutics Holdings Inc (SONN)

May 16, 2025

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 13, 2025

Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView

May 13, 2025

May 11, 2025

Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025

May 01, 2025

Sonnet Chief Medical Officer, Richard Kenney, M.D., to - GlobeNewswire

May 01, 2025

May 01, 2025

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit - The Globe and Mail

May 01, 2025

Apr 19, 2025

Chanticleer Holdings Little Big Burger Partner and Brand Ambassador Denny Hamlin Wins the Daytona 500 - marketscreener.com

Apr 19, 2025

Apr 16, 2025

Sonnet Releases Virtual Investor "What This Means" Segment | SONN Stock News - GuruFocus

Apr 16, 2025

Apr 16, 2025

Sonnet BioTherapeutics Discusses Positive Safety Data for SON-1010 in Virtual Investor Segment - Nasdaq

Apr 16, 2025

Apr 16, 2025

Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire

Apr 16, 2025

Apr 15, 2025

Biotech Leader Dr. Pankaj Mohan Honored on NASDAQ After Tragic Crash - newsindiatimes.com

Apr 15, 2025

Apr 08, 2025

Sonnet BioTherapeutics (NASDAQ:SONN) Receives Buy Rating from Chardan Capital - Defense World

Apr 08, 2025

Apr 07, 2025

SONN stock touches 52-week low at $1.18 amid market challenges - Investing.com India

Apr 07, 2025

Apr 07, 2025

Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial - Yahoo Finance

Apr 07, 2025

Apr 06, 2025

Sonnet BioTherapeutics advances in cancer trial - Investing.com Australia

Apr 06, 2025

Apr 04, 2025

Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener

Apr 04, 2025

Apr 04, 2025

Sonnet BioTherapeutics advances in cancer trial By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 04, 2025

Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks

Apr 04, 2025

Apr 04, 2025

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - The Manila Times

Apr 04, 2025

Apr 04, 2025

Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener

Apr 04, 2025

Apr 04, 2025

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in - GlobeNewswire

Apr 04, 2025

Apr 02, 2025

Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com Canada

Apr 02, 2025

Apr 01, 2025

Sonnet Announces Release of Corporate Update Video - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com

Apr 01, 2025

Apr 01, 2025

Sonnet BioTherapeutics Announces New Interim CEO Appointment - TipRanks

Apr 01, 2025

Apr 01, 2025

Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - NewsBreak: Local News & Alerts

Apr 01, 2025

Apr 01, 2025

Pilot killed in N.J. plane crash was biotech company founder, CEO - NJ.com

Apr 01, 2025

Apr 01, 2025

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz

Apr 01, 2025

Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com

Apr 01, 2025

Apr 01, 2025

Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - marketscreener.com

Apr 01, 2025

Mar 30, 2025

Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World

Mar 30, 2025

Mar 29, 2025

Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter

Mar 29, 2025

Mar 28, 2025

SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 28, 2025

Mar 27, 2025

Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire

Mar 27, 2025

Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener

Mar 26, 2025

Mar 26, 2025

Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan

Mar 26, 2025

Mar 21, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World

Mar 21, 2025

Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent - Investing.com

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - Yahoo

Mar 19, 2025

Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025

Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq

Mar 11, 2025

Mar 11, 2025

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan

Mar 11, 2025